|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2005; 45:2008-2011, doi:10.1016/j.jacc.2004.12.080 © 2005 by the American College of Cardiology Foundation |
University Health Network and Mount Sinai Hospital Department of Medicine and Sleep Research Laboratories of the Toronto Rehabilitation Institute, University of Toronto, Toronto, Canada.
Manuscript received July 15, 2004; revised manuscript received November 29, 2004, accepted December 6, 2004.
* Reprint requests and correspondence: Dr. John S. Floras, Suite 1614, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. (Email: john.floras{at}utoronto.ca).
 |
Abstract |
|---|
 Top Abstract MethodsResultsDiscussionReferences |
|---|
BACKGROUND: Daytime muscle sympathetic nerve activity (MSNA) is elevated in HF patients with coexisting OSA. In our recent randomized trial in HF, abolition of OSA by continuous positive airway pressure (CPAP) increased left ventricular ejection fraction (LVEF) and lowered morning systolic BP.
METHODS: Muscle sympathetic nerve activity, BP, and heart rate (HR) of medically treated HF patients (EF <45%) and OSA (apnea-hypopnea index 
20/h of sleep) were recorded on the morning after overnight polysomnography, and again one month after patients were randomly allocated nocturnal CPAP treatment or no CPAP (control).
RESULTS: In nine control patients, there were no significant changes in the severity of OSA, MSNA, systolic BP, or HR. In contrast, in the 8 CPAP-treated patients, OSA was attenuated, and there were significant reductions in daytime MSNA (from 58 ± 4 bursts/min to 48 ± 5 bursts/min; 84 ± 4 bursts/100 heart beats to 72 ± 5 bursts/100 heart beats; p < 0.001 and p = 0.003, respectively), systolic BP (from 135 ± 5 mm Hg to 120 ± 6 mm Hg, p = 0.03), and HR (from 69 ± 2 min–1 to 66 ± 2 min–1; p = 0.013).
CONCLUSIONS: Treatment of coexisting OSA by CPAP in HF patients lowers daytime MSNA, systolic BP, and HR. Inhibition of increased central sympathetic vasoconstrictor outflow is one mechanism by which nocturnal CPAP reduces awake BP in HF patients with moderate to severe OSA.
| ||||||||||||
15 apneic or hypopneic events per hour, is present in 4% to 9% of the adult North American population aged 30 to 60, but its reported prevalence in heart failure (HF) patients with impaired left ventricular (LV) systolic function is substantially higher—between 11% and 37% (1). Heart failure is a condition in which sympathetic activation in the awake state has been linked to premature mortality and sudden death (2). Obstructive sleep apnea-induced apnea, hypoxia, hypercapnia, and arousal trigger surges in central sympathetic vasoconstrictor outflow, peripheral resistance, and blood pressure (BP) during sleep (1). Individuals with normal LV systolic function and OSA exhibit increased muscle sympathetic nerve activity (MSNA) even while awake (3,4). This carryover effect is also evident in HF patients, in whom coexisting OSA is associated with higher daytime MSNA (5). In our recent randomized trial involving 24 HF patients (mean LV ejection fraction [LVEF] 27%) with coexisting OSA, 1 month of therapy with nocturnal continuous positive airway pressure (CPAP) caused a increase in daytime LVEF and a significant reduction in morning systolic BP (6). We considered attenuation of daytime sympathetic vasoconstrictor discharge a likely mechanism for this fall in BP. We therefore recruited additional patients to test the hypothesis that abolition of coexisting OSA in HF by CPAP would lower daytime MSNA.
|
Methods |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
45% (radionuclide angiography); 3) >3 months of stable optimal drug therapy at highest tolerated dose; 4) moderate to severe OSA (20 apneas and hypopneas/h of sleep) with >50% of events obstructive (1,7); and 5) sinus rhythm. Exclusion criteria included: 1) primary valvular heart disease; 2) cardiac pacing; and 3) unstable angina, myocardial infarction, or cardiac surgery within three months (6). Polysomnography. All subjects underwent a second baseline overnight polysomnographic study, with sleep stages, apneas, hypopneas, and arousals defined and scored as previously described (6,7). Oxyhemoglobin saturation (SaO2) was monitored by pulse oximetry. The apnea-hypopnea index (AHI) was calculated as the frequency of apneas and hypopneas/h of sleep.
Measurement of HR, BP, and MSNA. The next morning, the electrocardiogram, BP (digital photoplethysmography; Finapres 2300, Ohmeda, Englewood, Colorado) and peroneal MSNA were recorded over 15 min, with subjects awake, resting quietly supine, and breathing without apnea, as confirmed by respiratory inductance plethysmography. Muscle sympathetic nerve activity was expressed as burst frequency (bursts/min) and burst incidence (bursts/100 cardiac cycles) (8,9).
Protocol. Subjects were allocated randomly to either a control group (optimal HF drug therapy) or to a group that, in addition, received CPAP. The night after the baseline sleep study, the latter subjects underwent overnight CPAP titration, during which pressure was adjusted to abolish apneas and hypopneas or to the highest tolerated level. They were then provided a metered CPAP machine to document hours of use and were instructed to apply this for >6 h nightly. After one month the sleep study and the awake study were repeated.
Statistics. All data were acquired and analyzed by investigators blinded to the sequence of studies and treatment. Data are expressed as mean ± SEM. Analyses were performed using SigmaStat 2.03 (SPSS Inc., Chicago, Illinois). Baseline characteristics were compared by two-tailed unpaired t tests for continuous variables and the Fisher exact test for nominal variables. Two-way repeated measures analyses of variance, followed by Tukey’s test, were used to compare within- and between-group differences in variables obtained one month apart. A p value <0.05 was considered significant.
|
Results |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
|
In the control group, hemodynamic and microneurographic variables were similar on the two study days (Table 2). In CPAP-treated subjects, awake systolic BP fell by 15.4 ± 4.9 mm Hg (p = 0.015; p = 0.04 for the between-group comparison), as did HR (p = 0.013; p = 0.004 for between-group comparison). In contrast with control patients, there were significant reductions in MSNA burst frequency in all subjects (p < 0.001; p < 0.009 for between-group comparison). The MSNA burst incidence also fell (p = 0.003) after one month of CPAP treatment (Table 2, Figs. 1 and 2).
|
|
|
Discussion |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
These findings also provide new insight into the contribution of sympathetic vasoconstrictor tone to BP regulation in HF patients with coexisting OSA. Muscle sympathetic nerve activity is increased in most patients with HF, in whom it relates directly to resistance in the vascular bed distal to the recording electrode (12). However, there is considerable interindividual variation in sympathetic nerve firing rates in patients with systolic HF that cannot be explained simply on the basis of reflex responses to their altered hemodynamics (2,8). One potential source of such variation is the additional sympatho-excitatory influence of coexisting OSA. Upper airway obstruction not only activates the sympathetic nervous system of HF patients reflexively by eliciting apnea, hypoxia, hypercapnia, a fall in cardiac output, and arousal from sleep (1,9), but exposure to brief episodes of intermittent hypoxia evokes sympathetic activation and BP elevation that persist long after recovery from the hypoxic stimulus (13,14). Thus, recurrent obstructive apneas at night in HF patients could elicit sustained aftereffects on MSNA and BP that carry-over into the awake state. Consistent with this concept, in our series of 301 patients with HF, those with OSA had higher daytime systolic BP than those without, despite their receiving more antihypertensive therapy; systolic BP correlated directly with the AHI (15). We proposed that their higher awake BP was due in part to increased daytime sympathetic vasoconstrictor tone (5) that might be reduced if OSA were treated with CPAP.
In HF patients, acute abolition of obstructive apnea during sleep with CPAP causes immediate reductions in systolic BP and HR (16). In subjects with OSA but without HF, long-term treatment with CPAP lowers awake systolic BP (17). In our recent randomized trial involving medically treated HF patients with OSA, the addition of nocturnal CPAP increased mean daytime LVEF from 25% to 34%, yet at the same time lowered morning systolic BP by 10 ± 4 mm Hg (6). The present study is an extension of that trial, with the objective of testing the new hypothesis that abolition of obstructive apnea during sleep would abrogate its daytime sympatho-excitatory pressor aftereffects (5). Our demonstration of reductions in MSNA, systolic BP, and HR after one month of treatment of OSA by CPAP are consistent with this hypothesis and indicate that inhibition of sympathetic vasoconstrictor discharge is one mechanism by which nocturnal CPAP lowers daytime systolic BP in HF patients with moderate to severe OSA.
A similar randomized trial detected an absolute increase in daytime LVEF of 5% after 3 months of CPAP therapy, but no change in mean arterial BP (systolic BP was not reported) (18). Importantly, these authors recruited subjects with milder OSA (AHI >5 events/h) and HF (LVEF 55%) and presumably less baseline sympathetic activation. This cannot be confirmed, however, because neither MSNA nor daytime plasma norepinephrine were measured.
Four major risk factors for ventricular remodeling, myocyte loss, disease progression, and premature mortality in patients with impaired LV systolic function and OSA are 1) abrupt increases in negative intrathoracic and LV transmural pressures (i.e., afterload) and distending forces during obstructive apneas, resulting in increased myocardial energy requirements; 2) nocturnal hypoxia and oxidative stress; 3) nocturnal and daytime sympathetic activation; and 4) nocturnal and daytime hypertension. Treatment of HF patients with coexisting OSA by nocturnal CPAP addresses each of these risk factors and therefore has the potential to improve LV systolic function via several mechanisms. Compared with HF patients with normal breathing patterns during sleep, those with OSA are exposed to the adverse effects on the failing heart and circulation of increased central sympathetic outflow during sleep and when awake. By removing this additional apnea-induced stimulus to sympathetically mediated vasoconstriction, and thereby lowering systolic BP through specific therapy of coexisting OSA, nocturnal CPAP might improve the prognosis of HF patients with moderate to severe OSA. This hypothesis merits specific testing in a longer term outcome trial.
|
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractMethodsResultsDiscussionReferences |
|---|
Related Article
This article has been cited by other articles:
|
|
 |
|
  T. Kasai, K. Narui, T. Dohi, N. Yanagisawa, S. Ishiwata, M. Ohno, T. Yamaguchi, and S.-i. Momomura Prognosis of Patients With Heart Failure and Obstructive Sleep Apnea Treated With Continuous Positive Airway Pressure Chest, March 1, 2008; 133(3): 690 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Javaheri Treatment of obstructive and central sleep apnoea in heart failure: practical options Eur. Respir. Rev., December 1, 2007; 16(106): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Bazzano, Z. Khan, K. Reynolds, and J. He Effect of Nocturnal Nasal Continuous Positive Airway Pressure on Blood Pressure in Obstructive Sleep Apnea Hypertension, August 1, 2007; 50(2): 417 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Floras and T. D. Bradley Treating Obstructive Sleep Apnea: Is There More to the Story Than 2 Millimeters of Mercury? Hypertension, August 1, 2007; 50(2): 289 - 291. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Montserrat, F. Garcia-Rio, and F. Barbe Diagnostic and Therapeutic Approach to Nonsleepy Apnea Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Haentjens, A. Van Meerhaeghe, A. Moscariello, S. De Weerdt, K. Poppe, A. Dupont, and B. Velkeniers The Impact of Continuous Positive Airway Pressure on Blood Pressure in Patients With Obstructive Sleep Apnea Syndrome: Evidence From a Meta-analysis of Placebo-Controlled Randomized Trials Arch Intern Med, April 23, 2007; 167(8): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, J. D. Parker, G. E. Newton, J. S. Floras, S. Mak, K.-L. Chiu, P. Ruttanaumpawan, G. Tomlinson, and T. D. Bradley Influence of Obstructive Sleep Apnea on Mortality in Patients With Heart Failure J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1625 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yoshinaga, I. G. Burwash, J. A. Leech, H. Haddad, C. B. Johnson, R. A. deKemp, L. Garrard, L. Chen, K. Williams, J. N. DaSilva, et al. The Effects of Continuous Positive Airway Pressure on Myocardial Energetics in Patients With Heart Failure and Obstructive Sleep Apnea J. Am. Coll. Cardiol., January 30, 2007; 49(4): 450 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26 Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities Eur. Respir. J., January 1, 2007; 29(1): 156 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arzt and T. D. Bradley Treatment of Sleep Apnea in Heart Failure Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1300 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Esler and N. Eikelis Is obstructive sleep apnea the cause of sympathetic nervous activation in human obesity? J Appl Physiol, January 1, 2006; 100(1): 11 - 12. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mills, B. P. Kennedy, J. S. Loredo, J. E. Dimsdale, and M. G. Ziegler Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea J Appl Physiol, January 1, 2006; 100(1): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Spaak, Z. J. Egri, T. Kubo, E. Yu, S.-I. Ando, Y. Kaneko, K. Usui, T. D. Bradley, and J. S. Floras Muscle Sympathetic Nerve Activity During Wakefulness in Heart Failure Patients With and Without Sleep Apnea Hypertension, December 1, 2005; 46(6): 1327 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Bradley, A. G. Logan, R. J. Kimoff, F. Series, D. Morrison, K. Ferguson, I. Belenkie, M. Pfeifer, J. Fleetham, P. Hanly, et al. Continuous Positive Airway Pressure for Central Sleep Apnea and Heart Failure. N. Engl. J. Med., November 10, 2005; 353(19): 2025 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M Ryan, K Usui, J S Floras, and T D Bradley Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea Thorax, September 1, 2005; 60(9): 781 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Somers, A. S. Gami, and L. J. Olson Treating Sleep Apnea in Heart Failure Patients: Promises But Still No Prizes J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2012 - 2014. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
